BRCA1 and breast carcinoma: The breast cancer associated proteins BRCA1/2 function in the repair of DNA via homologous recombination; therefore, PARP inhibitors are approved for treatment of BRCA1/2 mutated breast, ovarian, and pancreas cancer (107).